# Format-dependent binder function

Source: https://onco.cc/terms/binder-format-constraints/  
OnCo record `binder-format-constraints` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A recognition domain can behave differently when built into a different therapeutic structure. Its final format is part of the experiment.

## Summary

Epitope-distance experiments in bispecific T-cell engagers linked target geometry to cell lysis in the tested models. A later comparison of CD123-directed single-chain and single-domain antibody fragments examined their behavior in engineered T cells and a mouse leukemia model. These are construct-specific findings. A successful binding measurement or one format comparison should not be generalized to all antibody fragments, targets, payloads or clinical settings. Three primary studies show what the assembled format adds. In mice with MUC16-positive xenografts, an anti-MUC16 antibody-drug conjugate made by site-specific cysteine conjugation was as effective as a conventional conjugate and was tolerated at higher doses in rats and cynomolgus monkeys (Junutula et al., 2008). CD19 CARs with a long IgG4 spacer worked in vitro but lacked antitumour activity in mice because the Fc region bound Fc receptors on myeloid cells and caused activation-induced T-cell death; modifying the CH2 domain restored activity (Hudecek et al., 2015). Antigen-independent clustering of scFvs triggered tonic CD3-zeta signalling and early exhaustion in the CARs studied, except the CD19 CAR, with 4-1BB reducing and CD28 increasing the effect (Long et al., 2015). FDA's 2024 CAR T guidance asks for in vitro and in vivo evaluation of antigen-dependent and antigen-independent activity of the complete product.

## Fields

- Kind: Term
- Last checked: 2026-11-10

## Notes

- There is no transferable best affinity. A measured affinity describes an interaction in a specified model, while behaviour also depends on target density, geometry, exposure and unwanted recognition. Bluemel et al. (2010) found BiTE constructs with similar affinity but very different lysis. Kinna et al. (2026) chose ten VHH and scFv pairs with comparable domain targeting and KD of 10^-9 to 10^-11 molar and still found differences in stability, in vitro cytokine release and survival in an acute myeloid leukaemia xenograft; the tumour was the human AML-derived MOLM-14 cell line in NSG mice, with generally five mice per group. The authors identify use of a single donor from the preceding in-vitro experiments as a limitation. This does not establish general superiority of either format or compare clinical products in patients.
- Format changes what is tested. A soluble molecule must stay intact and usable through manufacture, storage and exposure, and adding binding units or a chemical cargo can change its behaviour (Junutula et al., 2008, anti-MUC16 conjugate in mice, rats and monkeys). A CAR fixes the binder to a membrane and links contact to signalling, so spacer reach, target position, expression and clustering matter (Hudecek et al., 2015; Long et al., 2015). The same recognition sequence therefore does not guarantee the same performance.
- Healthy-cell inference. A target found on cancer cells may also occur at lower amounts on healthy cells, so a change that improves recognition of target-low cancer cells can also improve recognition of healthy cells that carry some target. Format testing has to ask about both. FDA's January 2024 CAR T guidance calls for in vitro and in vivo assessment of antigen-dependent and antigen-independent activity in the complete product.
- Assay card for format work. Input is the actual assembled molecule or receptor-bearing cells (aliquots are consumed). Conditions to state are target density, exposure time, cell state and relevant negative and healthy-cell controls. Outputs are kept separate: binding constants under their model, receptor-positive cell fractions, cytokine concentration and timed target-cell survival. Thresholds are prespecified and product-specific, with no transferable affinity or activation cutoff. Limits include aggregation, poor expression, geometry and background signalling, and a dish omits whole-body exposure and tissue context. The validation tier is product-specific laboratory characterisation, earlier evidence than clinical safety or benefit.

## Sources

- Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen.: https://doi.org/10.1007/s00262-010-0844-y
- Antibody format matters: A comparative analysis of VHH and scFv domains reveals superior in vivo CAR T cell function with VHH domains.: https://doi.org/10.1016/j.ymthe.2026.06.017
- Junutula et al., 2008: site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index: https://doi.org/10.1038/nbt.1480
- Hudecek et al., 2015: the nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity: https://doi.org/10.1158/2326-6066.cir-14-0127
- Long et al., 2015: 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors: https://doi.org/10.1038/nm.3838
- FDA: considerations for the development of CAR T cell products (January 2024): https://www.fda.gov/media/156896/download

## Connected records

- terms: [Binder affinity, epitope and developability](https://onco.cc/terms/binder-affinity-epitope-developability/), [Binders as targeting modules](https://onco.cc/terms/binder-targeting-module/), [Immune measurements and product evidence](https://onco.cc/terms/immune-product-evidence/), [Single-chain and single-domain antibody fragments](https://onco.cc/terms/scfv-vhh-formats/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)

---
JSON: https://onco.cc/api/v1/entities/binder-format-constraints.json